Vaccinated individuals had a reduced risk of PCR-confirmed COVID-19 infection in comparison with non-vaccinated people.

A national prospective cohort study was performed to analyze the uptake of the COVID-19 vaccine and the efficacy of BNT162b2 mRNA against SARS-CoV-2 infection.

A total of 82,959 health care workers were examined. Utilizing linked and routinely gathered national-scale data within SAIL databank, the uptake of COVID-19 vaccines and the effectiveness of the vaccine against SARS-CoV-2 was analyzed. Data were available on 82,959 medical care workers with exposure extending to twenty-six weeks following 2nd doses.

The overall vaccine uptake was reported to be high (90%), with the majority of the medical care workers getting the BNT162b2 vaccine (79%). The uptake of the vaccine varied by socioeconomic status, age and staff role. Compared to people aged 16 to 29 years, people aged 50 to 59 and 60 plus years old were 1.6 times more probable to receive vaccination. When compared to midwifery and nursing staff, the allied health practitioners, and dental and medical staff were 1.1 and 1.5 times more potential to get vaccinated.

The efficacy of the BNT162b2 vaccine was noted to be consistent and strong throughout the characteristics examined. The vaccine efficacy was noted to be 52% three to six weeks following 1st dose, 86% from 2 weeks following the 2nd dose. However, this dropped to 53% from 22 weeks following 2nd dose.

The overall vaccine uptake was high in health care workers. High vaccine effectiveness for BNT162b2 was noted. The second dose of vaccine offered long term and better protection than the first dose.